IntelGenx Announces Commercial Launch of RIZAPORT® in Spain | 2021-09-07 | Press Releases

0

SAINT LAURENT, Quebec, Sep 07, 2021 (GLOBE NEWSWIRE) – IntelGenx Corp. (TSX V: IGX) (OTCQB: IGXT) (the “Company” or “IntelGenx”) today announced that Exeltis Healthcare SL (“Exeltis”), its marketing partner in the European Union (“EU”) ) for RIZAPORT®, a unique product for the treatment of acute migraines, has launched the product in Spain.

RIZAPORT® is a proprietary thin-film oral formulation of rizatriptan benzoate, a 5-HT1 receptor agonist and the active drug from Maxalt from Merck & Co.®. Rizatriptan is considered to be one of the most effective oral triptans, a class of molecules that constrict blood vessels in the brain to relieve swelling and other symptoms of migraine.1 RIZAPORT® is based on IntelGenx proprietary VersaFilm® Technology. It dissolves quickly and releases its active ingredient in the mouth. The method of administration of RIZAPORT® the oral soluble film, which does not require the patient to swallow a pill or consume water, as well as its neutral flavor, presents a therapeutic alternative for migraine patients, especially for those who suffer from migraine-related nausea, estimated at around 80% of the total migraine patient population, and for patients with dysphagia (difficulty swallowing).1

“This is the first VersaFilm®product based on the global pharmaceutical market launch and follows IntelGenx ‘recent transition to a commercial stage, ”said Dr. Horst G. Zerbe, CEO of IntelGenx. “The European migraine medication market is large and growing. It was valued at over US $ 1 billion in 2019 and is expected to approach US $ 1.5 billion by 2024.2 We look forward to continuing to support Exeltis’ launch of RIZAPORT® in Spain, as well as its plans to offer this therapy to migraine patients in other EU countries in the future. ”

“We are delighted to bring this innovative and easy-to-administer treatment to migraine patients in Spain,” said Alberto Fabregas, Managing Director of Exeltis Healthcare. “We are also looking forward to continuing our collaboration with IntelGenx and launching RIZAPORT® in other markets. ”

The references:

1 Láinez MJA. (2006) Rizatriptan in the treatment of migraine. Neuropsychiatrist Dis Treat. September 2006; 2 (3): 247-259.

2 Lipton RB, Buse DC, Saiers J, Fanning KM, Serrano D, Reed ML. (2013) Frequency and Burden of Headache-Related Nausea: Findings from the US Migraine Prevalence and Prevention Study (AMPP), Headache. 2013 Jan; 53 (1): 93-103.

3 Market data forecasts. “Europe Migraine Drugs Market Industry Report 2019-2024. Market Data Forecast, Aug 18, 2020, www.marketdataforecast.com/market-reports/europe-migraine-drug-Market.

About Exeltis Healthcare SL

Exeltis is a fast growing division of the integrated health sciences group Insud Pharma. With a global presence spanning over 40 countries, Exeltis has a team of over 4,000 professionals supported by a global manufacturing network. It enjoys a leading position in the women’s health segment, offering a broad portfolio of products to meet the needs of women in the areas of fertility, reproductive health, contraception, pregnancy, childbirth and menopause. In WHC, Exeltis’ The overarching goal is to support and care for women at every stage of life. In recent years, Exeltis has also branched out into the central nervous system (CNS) as a major area of ​​growth. Certain indications, such as migraine, are preferred because of its synergy with WHC.

About IntelGenx

IntelGenx is a leading drug distribution company focused on the development and manufacture of pharmaceutical films.

IntelGenx ‘superior film technologies, including VersaFilm®, DisinteQ ™, VetaFilm ™ and Transdermal VevaDerm ™, enable next-generation pharmaceuticals that address unmet medical needs. IntelGenx ‘innovative product pipeline provides significant benefits to patients and physicians for many therapeutic conditions.

IntelGenx’s highly skilled team provides comprehensive pharmaceutical services to pharmaceutical partners, including R&D, analytical method development, clinical oversight, intellectual property, and regulatory services. IntelGenx’s state-of-the-art manufacturing facility provides full service by providing laboratory scale production to pilot and commercial scale. For more information visit www.intelgenx.com.

Forward-looking statements:

This document may contain forward-looking information about IntelGenx’s results of operations and business prospects that involves substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx’s plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words “may”, “s” expect ”,“ anticipate ”,“ hear ”,“ plan ”,“ believe ”,“ seek ”,“ estimate ”,“ might ”,“ would ”and similar expressions. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Since these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx’s actual results could differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under “Risk Factors” in IntelGenx’s Annual Report on Form 10-K, filed with the Securities and Exchange United States Commission and available at www.sec.gov, and also filed with the Canadian Securities Administrators at www.sedar.com. IntelGenx assumes no obligation to update these forward-looking statements.

The TSX Venture Exchange and the OTCQB have neither approved nor disapproved the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Source: IntelGenx Technologies Corp.

For IntelGenx:

Stephen kilmer

Investor Relations

(514) 331-7440 ext 232

[email protected]

Or

André Godin, CPA, CA

President and Chief Financial Officer

IntelGenx Corp.

(514) 331-7440 ext 203

[email protected]

Main logo


Source link

Leave A Reply

Your email address will not be published.